《大行報告》瑞銀下調諾誠健華-B(09969.HK)目標價至16.2元 評級「買入」
瑞銀發表研究報告指,在核心產品Orelabrutinib的銷售提升帶動下,諾誠健華(09969.HK)中期收入按年增長142%,但由於期內研發開支增加及帳面匯率虧損所影響,中期虧損擴大至4.4億元人民幣。
報告指出,看好公司在研發方面的進步,期待未來12個月將迎來催化劑,其中今年起Orelabrutinib納入醫保報銷,銷售範圍覆蓋中國260多個城市及1,000多家醫院的推動,市場數據顯示該產品在三種獲批的 BTK抑製劑中的市場份額已提升至7.8%。
該行將Orelabrutinib在用於治療復發難治性邊緣區淋巴瘤(r/r MZL)的成功率預測從85%提高到95%,並根據產品管線研發及獲批進度,下調其2022至2024年收入預測,目標價由17.7元降至16.2元,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.